Restored Capillary Density in Spared Myocardium of Infarcted Rats Improves Ischemic Tolerance
- 1 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 40 (3) , 370-380
- https://doi.org/10.1097/00005344-200209000-00006
Abstract
Myocardial infarction (MI)–induced hypertrophy is associated with a decreased capillary density, which may negatively affect ischemic tolerance of the spared myocardium. The current study investigated the effects of moxonidine, a centrally acting sympatholytic, on left ventricular (LV) hypertrophy and capillary density in relation to sensitivity to ischemia in infarcted hearts. Infarcted rats were randomized to receive 3 or 6 mg/kg/d of moxonidine from 1 to 21 days after MI. LV hypertrophy after MI was indicated by increased ventricular to body weight ratio and was significantly inhibited by moxonidine. Histologic analysis revealed that MI-induced concentric hypertrophy of the spared myocardium, as indicated by almost double cross-sectional area of Gomori-stained myocytes, was completely prevented by 6 mg/kg/d of moxonidine. This effect was accompanied by a a restored number of lectin-stained capillaries per tissue area. However, capillary-to-myocyte ratio was similar in all groups. LV dysfunction after MI, measured in isolated perfused hearts, was confirmed by decreased LV systolic pressure and +dP/dtmax and was not affected by moxonidine. Low-flow ischemia, induced by lowering perfusion pressure from 85 to 15 mm Hg for 30 min, resulted in a further reduction of cardiac perfusion compared with sham rats, which was normalized with 6 mg/kg/d of moxonidine. Ischemic sensitivity in MI hearts, as reflected by increased maximal coronary flow during reperfusion, was reduced with moxonidine. This was further supported by substantially lower purines and lactate concentrations in the coronary effluent during ischemia. These results indicate that moxonidine-induced prevention of hypertrophy may preserve capillary density without affecting capillary number, thereby improving ischemic tolerance of the spared myocardium.Keywords
This publication has 28 references indexed in Scilit:
- Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure modelEuropean Journal of Pharmacology, 2000
- Early captopril treatment inhibits DNA synthesis in endothelial cells and normalization of maximal coronary flow in infarcted rat hearts.Cardiovascular Research, 1998
- Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic bandingCardiovascular Research, 1996
- Cardiac angiotensin converting enzyme and myocardial fibrosis in the ratCardiovascular Research, 1994
- Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.Circulation, 1994
- I1-Imidazoline-Receptor Agonists in the Treatment of Hypertension: An Appraisal of Clinical ExperienceJournal of Cardiovascular Pharmacology, 1994
- Coronary vascular mechanisms involved in decompensation from hypertrophy to heart failureJournal of the American College of Cardiology, 1993
- Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarctionJournal of Molecular and Cellular Cardiology, 1991
- Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth.Circulation Research, 1986
- Release of adenosine, inosine and hypoxanthine from the isolated guinea pig heart during hypoxia, flow-autoregulation and reactive hyperemiaPflügers Archiv - European Journal of Physiology, 1977